Recombinant human follicle-stimulating hormone: a scientific step to clinical improvement

Reproductive BioMedicine Online

Volumn 2, Issue 1, 2001, Pages 54-64

  Hugues, J N ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

anovulation; assisted reproductive technology; follicle stimulating hormone; in vitro fertilization; intracytoplasmic sperm injection; recombinant human FSH

Indexed keywords

CHORIONIC GONADOTROPIN; FOLLITROPIN; RECOMBINANT DNA; RECOMBINANT FOLLITROPIN;

CHO CELL LINE; CLINICAL PHARMACOLOGY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO TRANSFER; FRANCE; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; METABOLIC CLEARANCE RATE; NONHUMAN; OUTCOME ASSESSMENT; OVULATION INDUCTION; PREGNANCY RATE; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 85006356905     PISSN: 14726483     EISSN: 14726491     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)62188-8     Document Type: Review

References (75)

1. Afnan MA, Kennefick A 1999 Recombinant gonadotrophins: is there a difference in the tolerability of these products? 15th Annual Meeting of the European Society of Human Reproduction and Embryology, Tours, France, 27-30 June 1999 (abstract).
2. Albano, C, Smitz, J, Camus, M, et al. Pregnancy and birth in an in-vitro fertilization cycle after ovarian stimulation in a woman with a history of allergic reactions to human menopausal gonadotrophin. Human Reproduction 11 (1996), 1632–1634.
3. Auray, JP, Duru, G, Daya, S, et al. Pharmacoeconomic modelling in assisted reproduction technologies: recombinant FSH versus urinary FSH. ISPOR Third Annual Conference, Antwerp, Belgium 7-10 November 2000 Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 3, 2000, 341 (abstract).
4. Balasch, J, Fabregues, F, Penarrubia, J, et al. Follicular development and hormonal concentrations following highly purified or recombinant follicle-stimulating hormone administration in ovulatory women and WHO Group II anovulatory infertile patients. Journal of Assisted Reproduction and Genetics 15 (1998), 552–559.
5. Bergh, C, Howles, CM, Borg, K, et al. Recombinant human follicle stimulating hormone (r-hFSH, Gonal-F) versus highly ¯ purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques. Human Reproduction 12 (1997), 2133–2139.
6. Breckwoldt, M, Peters, F, Geistövel, F, Classification and diagnosis of ovarian insufficiency. Insler, V, Lunenfeld, B, (eds.) Infertility: Male and Female, 1986, Churchill Livingstone, Edinburgh, UK, 191–212.
7. Brinsden, P, Akagbosu, F, Gibbons, L, et al. A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization - embryo transfer. Fertility and Sterility 73 (2000), 114–116.
8. Camier B, Avril C, Cohen J et al. 1998 A multicentre, prospective, randomized study to compare a low dose protocol versus conventional administration of recombinant human follicle ¯ stimulating hormone (Gonal-F) in normo-responder women undergoing IVF/ICSI. 14th Annual Meeting of the European Society of Human Reproduction and Embryology, Gothenburg, Sweden, 21-24 June 1998 (abstract).
9. Coelingh Bennink, HJ, Fauser, BC, Out, HJ, Recombinant follicle¯ stimulating hormone (FSH; Puregon) is more efficient than ¯ urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotrophic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group. Fertility and Sterility 69 (1998), 19–25.
10. Dahl, KD, Stone, MP, FSH isoforms, radioimmunoassays and their significance. Journal of Andrology 13 (1992), 11–22.
11. D'Antonio, M, Borrelli, F, Datola, A, et al. Biological characterization of recombinant human follicle stimulating hormone isoforms. Human Reproduction 14 (1999), 1160–1167.
12. Daya, S, Menopausal gonadotrophin for in vitro fertilization: results of a meta-analysis. Hormone Research 43 (1995), 224–229.
13. Daya, S, Gunby, J, Recombinant versus urinary follicle-stimulating hormone for ovarian stimulation in assisted reproduction. Human Reproduction 14 (1999), 2207–2215.
14. De Leeuw, R, Mulders, J, Voortman, G, et al. Structure-function relationship of recombinant follicle stimulating hormone ¯ (Puregon). Molecular Human Reproduction 2 (1996), 361–369.
15. Devroey, P, Mannaerts, B, Smitz, J, et al. First established pregnancy and birth after ovarian stimulation with recombinant human follicle stimulating hormone (Org 32489). Human Reproduction 8 (1993), 863–865.
16. Devroey, P, Mannaerts, B, Smitz, J, et al. Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens. Human Reproduction 9 (1994), 1064–1069.
17. Devroey, P, Ubaldi, F, Smitz, J, et al. Recombinant follicle stimulating hormone. Assisted Reproduction Review 4 (1994), 2–9.
18. Devroey, P, Tournaye, H, Van Steirteghem, A, et al. The use of a 100 IU starting dose of recombinant follicle stimulating hormone ¯ (Puregon) in in-vitro fertilization. Human Reproduction 13 (1998), 565–566.
19. Dias, JA, Zhang, Y, Liu, X, Receptor binding and functional properties of chimeric human follitropin prepared by an exchange between a small hydrophilic intercysteine loop of human follitropin and human lutropin. Journal of Biological Chemistry 269 (1994), 25289–25294.
20. Dierich, A, Ram Sairam, M, Monaco, L, et al. Impairing follicle-stimulating hormone (FSH) signalling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proceedings of the National Academy of Sciences of the United States of America 95 (1998), 13612–13617.
21. European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. Journal of Clinical Endocrinology and Metabolism 83 (1998), 1507–1514.
22. Fisch, B, Avrech, OM, Pinkas, H, et al. Superovulation before IVF by recombinant versus urinary human FSH (combined with a long GnRH analog protocol): a comparative study. Journal of Assisted Reproduction and Genetics 12 (1995), 26–31.
23. Forti, G, Krausz, C, Clinical Review 100. Evaluation and treatment of the infertile couple. Human Reproduction 83 (1998), 4177–4188.
24. Franco JG Jr, Baruffi RLR, Coehlo J et al. 1999 A prospective and randomized study of ovarian stimulation for ICSI with recombinant FSH versus highly purified urinary FSH. 11th World Congress on In Vitro Fertilization and Human Reproduction Genetics, Sydney, NSW (Australia), 9-14 May 1999 (abstract).
25. Frydman R, Howles CM, Truong F 2000 A double-blind, randomized study to compare recombinant human follicle stimulating hormone ¯ (r-hFSH, Gonal-F) and highly purified urinary FSH (Metrodin ¯ HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French.
26. Multicentre Trialists. Human Reproduction 15, 520-525.
27. Germond, M, Dessole, S, Senn, A, et al. Successful in vitro fertilization and embryo transfer after treatment with recombinant human FSH. Lancet, 339, 1992, 1170.
28. Giudice, E, Crisci, C, Eshkol, A, et al. Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophic proteins. Human Reproduction 9 (1994), 2291–2299.
29. Hamberger, L, Wikland, M, Controversies in assisted reproduction. Natural versus stimulated cycles for IVF. Journal of Assisted Reproduction and Genetics 10 (1993), 405–406.
30. Harlin, J, Csemiczky, G, Wramsby, H, et al. Recombinant follicle stimulating hormone in in-vitro fertilization treatment - clinical experience with follitropin a and follitropin β. Human Reproduction 15 (2000), 239–244.
31. Hazout A, Pouly JL, Buvat J et al. 1998 A prospective, randomized, multicentre study comparing low dose versus conventional dose GnRH agonist in a long protocol using recombinant human ¯ follicle stimulating hormone (Gonal-F) in women undergoing in-vitro fertilization. 14th Annual Meeting of the European Society of Human Reproduction and Embryology, Gothenburg, Sweden, 21-24 June 1998 (abstract).
32. Hedon, B, Out, HJ, Hugues, JN, et al. Efficacy and safety of ¯ recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial. Human Reproduction 10 (1995), 3102–3106.
33. Hedon, B, Hugues, JN, Emperaire, JC, et al. A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. Human Reproduction 13 (1998), 2688–2692.
34. Homburg, R, Armar, NA, Eshel, A, et al. Influence of serum luteinizing hormone concentrations on ovulation, conception and early pregnancy loss in polycystic ovarian syndrome. British Medical Journal 297 (1988), 1024–1026.
35. Homburg, R, Levy, T, Ben-Rafael, Z, A comparative prospective study of conventional regimen with chronic low dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertility and Sterility 63 (1995), 729–733.
36. Hornnes, P, Giroud, D, Howles, C, et al. Recombinant human follicle-stimulating hormone treatment leads to normal follicular growth, estradiol secretion and pregnancy in a World Health Organization Group II anovulatory woman. Fertility and Sterility 60 (1993), 724–726.
37. Howles, CM, Genetic engineering of human FSH (Gonal-F ¯). Human Reproduction Update 2 (1996), 133–190.
38. Howles, CM, Loumaye, E, Giroud, D, et al. Multiple follicular development and ovarian steroidogenesis following s.c. administration of a highly purified urinary FSH preparation ¯ (Metrodin HP) in pituitary desensitized women undergoing IVF-embryo transfer: a multicentre European Phase III study. Human Reproduction 9 (1994), 424–430.
39. Hughes, EG, Fedorkow, DM, Daya, S, et al. The routine use of gonadotrophin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertility and Sterility 58 (1992), 888–896.
40. Hull, MGR, Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecological Endocrinology 1 (1987), 235–245.
41. Jansen, CAM, van Os, HC, Out, HJ, et al. A prospective, randomized clinical trial comparing recombinant follicle ¯ stimulating hormone (Puregon) and human menopausal ¯ gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization cycles. Human Reproduction 13 (1998), 2995–2999.
42. Keene, JL, Matzuk, MM, Otani, T, et al. Expression of biologically active human follitropin in Chinese hamster ovary cells. Journal of Biological Chemistry 264 (1989), 4769–4775.
43. Kelly, EE, Nebiolo, L, Recombinant FSH therapy alone versus combination therapy with recombinant LH therapy in patients down-regulated with a low-dose luteal GnRH agonist protocol: preliminary results. Jansen, R, Mortimer, D, Coote, K, (eds.) Towards reproductive certainty: fertility & genetics beyond 1999, 1999, Parthenon Publishing Group, Carnforth, UK, 200–204.
44. Khalaf Y, Taylor A, Pettigrew R et al. 1998 The relative clinical efficacy of recombinant follicle stimulating hormone to the highly purified urinary preparation. 14th Annual Meeting of the European Society of Human Reproduction and Embryology, Gothenburg, Sweden, 21-24 June 1998 (abstract).
45. Lenton, E, Soltan, A, Hewitt, J, et al. Induction of superovulation in women undergoing assisted reproductive techniques: recombinant human follicle stimulating hormone (follitropin a) versus highly purified urinary FSH (urofollitropin HP). Human Reproduction 15 (2000), 1021–1097.
46. Li, TC, Hindle, JE, Adverse local reaction to intramuscular injections of urinary-derived gonadotrophins. Human Reproduction 8 (1993), 1835–1836.
47. Loumaye, E, The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer. Human Reproduction 5 (1990), 357–376.
48. Loumaye, E, Porchet, H, Beltrami, V, et al. Ovulation induction with recombinant human follicle stimulating hormone and luteinizing hormone. Filicori, M, Flamigni, C, (eds.) Ovulation induction: basic science and clinical advances, 1994, Elsevier Science B V, Amsterdam, The Netherlands, 227–236.
49. Loumaye, E, Campbell, R, Salat-Baroux, J, Human follicle-stimulating hormone produced by recombinant DNA technology: a review for clinicians. Human Reproduction Update 1 (1995), 188–199.
50. Manassiev NA, Davies WAR, Leonard T et al. 1997 Initial results from the comparison of recombinant FSH and urinary FSH in an IVF programme. Human Reproduction 12 (abstract book 1), 13th Annual Meeting of the European Society of Human Reproduction and Embryology, Edinburgh, UK, 1997 (abstract).
51. Mulders, JWM, Wijn, H, Theunissen, F, et al. Prediction of the in-vivo biological activity of human recombinant follicle-stimulating hormone using quantitative isoelectric focusing: optimization of the model. Pharmaceutical and Pharmacological Communications 5 (1999), 51–55.
52. Olijve, W, De Boer, W, Mulders, JWM, et al. Molecular biology and biochemistry of human recombinant follicle stimulating ¯ hormone (Puregon). Molecular Human Reproduction 2 (1996), 371–382.
53. Out, HJ, Mannaerts, BMJL, Driessen, SGAJ, et al. A prospective, randomized assessor-blind, multicentre study comparing ¯ recombinant and urinary follicle-stimulating hormone (Puregon ¯ versus Metrodin) in in-vitro fertilization. Human Reproduction 10 (1995), 2534–2540.
54. Out, HJ, Driessen, SGAJ, Mannaerts, BMJL, et al. Recombinant ¯ follicle-stimulating hormone (follitropin β, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotrophins. Fertility and Sterility 68 (1997), 138–142.
55. Out, HJ, Reimitz, PE, Coelingh Bennink, HJT, A prospective, randomized study to assess the tolerance and efficacy of intramuscular and subcutaneous administration of recombinant ¯ follicle-stimulating hormone (Puregon). Fertility and Sterility 67 (1997), 278–283.
56. Out, HJ, Lindenberg, S, Mikkelsen, AL, et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating ¯ hormone (Puregon) in women undergoing ovarian stimulation. Human Reproduction 14 (1999), 622–627.
57. Punnonen, R, Ashorn, R, Vilja, P, et al. Spontaneous luteinizing hormone surge and cleavage of in vitro fertilized embryos. Fertility and Sterility 49 (1988), 479–482.
58. Recombinant Human FSH Study Group. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertility and Sterility 63 (1995), 77–86.
59. Rizk, P, Smitz, J, Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Human Reproduction 7 (1992), 430–440.
60. Schats, R, Sutter, PD, Bassil, S, et al. Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of the Feronia and Apis study group. Human Reproduction 15 (2000), 1691–1697.
61. Scott Sills, E, Levy, DP, Moomjy, M, et al. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization. Human Reproduction 14 (1999), 2230–2235.
62. Smitz, J, Devroey, P, Braeckmans, P, et al. Management of failed cycles in an IVF-GIFT programme with the combination of a GnRH analogue and HMG. Human Reproduction 2 (1987), 309–314.
63. Stanger, JD, Yovich, JL, Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone concentrations during the follicular phase. British Journal of Obstetrics and Gynaecology 92 (1985), 385–392.
64. Stanton, PG, Robertson, DM, Burgon, PG, et al. Isolation and physicochemical characterization of human follicle-stimulating hormone isoforms. Endocrinology 139 (1992), 2820–2832.
65. Steelman, SL, Pohley, FM, Assay of follicle stimulating hormone based on the augmentation with human chorionic gonadotrophin. Endocrinology 53 (1953), 604–616.
66. Strowitzki, T, Kentenich, H, Kiesel, L, et al. Ovarian stimulation in women undergoing in-vitro fertilization and embryo transfer using ¯ recombinant human follicle stimulating hormone (Gonal-F) in non-down regulated cycles. Human Reproduction 10 (1995), 3097–3101.
67. Templeton, A, Morris, JK, Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. New England Journal of Medicine 339 (1998), 573–577.
68. Thornton, SJ, Starting doses in IVF and effects on outcome. Human Reproduction, 11, 1996, 104 (abstract).
69. Timossi, C, Damian-Matsumara, P, Dominguez-Gonzales, A, et al. A less acidic human FSH preparation induces tissue-type plasminogen activator enzyme activity earlier than a predominantly acidic analogue in phenobarbital-blocked pro-oestrous rats. Molecular Human Reproduction 11 (1998), 1032–1038.
70. Ulloa-Aguirre, A, Midley, AR, Beitins, IZ, et al. Follicle-stimulating isohormones: characterization and physiological relevance. Endocrine Review 16 (1995), 765–787.
71. Van Dessel, HJ, Donderwinkel, PF, Coelingh Bennink, HJ, et al. First established pregnancy and birth after induction of ovulation with recombinant human follicle-stimulating hormone in polycystic ovary syndrome. Human Reproduction 9 (1994), 55–56.
72. Van Loon, K, In utero exposure to gonadotrophins. Shoham, Z, Howles, CM, Jacobs, H, (eds.) Female infertility therapy: current practice, 1998, Martin Dunitz, London, UK, 3–9.
73. White, DM, Polson, DW, Kiddy, D, et al. Extensive personal experience. Induction of ovulation with low dose gonadotrophins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. Journal of Clinical Endocrinology and Metabolism 81 (1996), 3821–3824.
74. Wikland, M, Borg, J, Hamberger, L, et al. Simplification of IVF, minimal monitoring and the use of subcutaneous highly purified FSH administration for ovulation induction. Human Reproduction 9 (1994), 1430–1436.
75. Yarali, H, Bukulmez, O, Gurgan, T, Urinary follicle-stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate-resistant, normogonadotrophic, chronic anovulation: a prospective randomized study. Fertility and Sterility 72 (1999), 276–281.